Colon cancer screening is only effective if you complete the test. With 53,000 Americans expected to die from colon cancer in ...

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal ...

Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA ApprovalBERKELEY ...

According to Guardant’s website, Medicare Part B (Medical Insurance) covers a blood-based biomarker screening test to check for colorectal cancer if the individual is between the ages of 45–85, shows ...

Cases of colorectal cancer have been rapidly increasing among young adults, so we spoke to a doctor to get some helpful tips.

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...

The Health Promotion Administration (HPA) is to increase public funding for painless colonoscopy screenings for high-risk ...

to support commercialization of Mainz Biomed’s NextGen screening test for colorectal cancer. Mainz Biomed’s stool-based ColoAlert test is designed to detect colorectal cancer tumor DNA to aid ...

Expanded eligibility criteria and new tests for national cancer screening programs are to be introduced on Wednesday next ...